Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Summary

The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Ulcerative Colitis (UC)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 to 75 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Xencor, Inc.

Last updated on ClinicalTrials.gov

September 29, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites